Response to Moolenaar et al. Lee and Lynch (2005) extended the findings by demonstrating that recombinant L. reclusa SMD hydrolzses various lysophospholipids and identified specific histidine residues that are essential for the enzyme activity. Pettus et al. (2003 Pettus et al. ( , 2004 in two consequential investigations provided evidence that ceramide-1-phosphate (C1P) interacts directly with cytosolic phospholipase A 2 (cPLA 2 ) acting as an activator of cPLA 2 and subsequent inflammatory response. They determined that in A549 lung adenocarcinoma cells, natural and endogenous (produced by SMD) C1Ps were potent and specific inducers of arachidonic acid and prostanoid synthesis. The treatment of A549 cells with SMD resulted in a threefold increase in arachidonic acid release. Using RNAmediated interference technology, Pettus et al. confirmed in A549 and in J774.1 microphages that cPLA 2 was downstream of C1P. It was also found that in A549 cells, C1P caused translocation of cPLA 2 to membranes. Their in vitro binding studies disclosed that C1P directly binds and activate with fulllength cPLA 2 . Other publications regarding biological activities of C1P are reviewed in details by Gomez-Munoz (2004) .
The focus of our investigation was the expression pattern of human fibroblasts treated with recombinant SMD to gain insight into cellular mechanisms of loxoscelism pathology. We observed a dose-and time-dependent upregulation of several cytokines (data not shown). The pattern of continuous increase was present up to 18 hours of treatment (data not shown). Although we recognize the evidence that lysophospholipase D activity of SMD is obviously an important factor in loxoscelism, we are not convinced that the sphingomyelin-ceramide pathway involvement in the L. reclusa pathology can be ignored. More than one mechanism of action is also possible in this pathology and further investigation would benefit the understanding of the complex immunological response following spider envenomation. , 1997; Lorand and Graham, 2003) . Serum antibodies against TG2 can be sensitive and specific for DH as well as celiac disease (Dieterich et al., 1999) . Sardy et al. (2002) hypothesized that an autoantigen related to TG2 could explain the presentation of DH and reported that epidermal transglutaminase (TG3) deposits with IgA in perilesional biopsies in patients with DH. IgA deposits can occur in regions that are not clinically involved (Fry et al., 1978; Zone et al., 1996) . To confirm the involvement of TG3 in DH and to determine whether TG3 deposits are restricted to perilesional skin, we have raised a new goat antibody against human TG3.
CONFLICT OF INTEREST
In a series of nine DH patients with active disease, we compared direct immunofluorescence (DIF) for IgA and TG3 in perilesional and uninvolved skin. We also compared serology for TG2 and TG3 and results from DIF for IgA and TG3 in the context of a glutenfree diet (GFD). The protocol was approved by our Institutional Review Board, patients consented in writing, and we adhered to the Declaration of Helsinki Principles. All patients had a diagnosis of DH established by skin biopsy showing granular IgA and had active disease. Adherence to GFD was reported by patients as strict or poor.
Serum was analyzed for IgA antibodies against TG2, TG3, and endomysium endomysial antibody (EMA). Semiquantitative detection of anti-TG2 and -TG3 were performed using ELISA (INOVA Diagnostics, San Diego, CA, and Immunodiagnostik AG, Bensheim, Germany). EMA were detected using indirect immunofluorescence on monkey esophagus (University of California at Davis) (Unsworth, 1996) . Patient age, sex, family history, adherence to GFD, dapsone use, and serologies for antibodies against TG2, TG3, and endomysium are represented in Table 1 . Five patients reported strict adherence to a GFD. Among patients adhering to a strict GFD, four of five (80%) were negative by IgA ELISA for anti-TG2 antibodies and EMA. All four patients reporting poor GFD adherence had anti-TG2 antibodies and two of four were positive by EMA. All five patients in the strict GFD group were seronegative for anti-TG3 antibodies and all four patients in the poor GFD group were positive. The two patients with negative EMA had the lowest values for anti-TG2.
Polyclonal TG3 antibody
Purified TG3 expressed from a baculovirus system was used to produce polyclonal antibodies in goats (Ahvazi and Steinert, 2003) . Purified TG3 was a kind gift from Dr Bijan Ahazi. To confirm reactivity and specificity, Western blots were performed using the baculovirus-produced TG3 as well as separately cloned TG2 and TG3. Complementary DNAs for TG3 and TG2 were isolated by RT-PCR from human keratinocytes using primers published by Sardy et al., and were sequence confirmed. Complementary DNA was cloned in the Invitrogen pSecTag2/ Hygro B vector, lysates were purified using a Ni 2 þ column (Invitrogen, Carlsbad, CA, USA), electrophoresed, and transferred to nitrocellulose blots. IgG was prepared using a Protein G column. Western blots confirmed a high titer against both TG3 clones. Specificity was demonstrated by lack of reactivity against non-transfected human embryonic kidney lysate, recombinant TG2 (Figure 1) , and serum and secretory (colostral) IgA (not shown). Further specificity was established by lack of reactivity on IIF when reacted with skin from three patients with linear IgA bullous dermatosis (Figure 2e and f) , two with Henoch--Abbreviations: DIF, direct immunofluorescence; DH, dermatitis herpetiformis; EMA, endomysial antibody; GFD, gluten-free diet; TG2, transglutaminase 2 or tissue transglutaminase; TG3, transglutaminase 3 or epidermal transglutaminase
